53 Days
Source:
وكالة صدى نيوز
Positive early data on pancreatic cancer vaccine
A US clinical study has shown that an experimental vaccine targeting genetic mutations associated with pancreatic cancer, particularly the "KRAS" mutation, successfully triggered a strong and long-lasting immune response in individuals at risk due to aging and pancreatic changes. The vaccine, named "mKRAS-VAX," was tested on 20 participants with genetic factors linked to pancreatic cancer, and the results indicated that 90% of them developed an effective immune response. These immune responses persisted for up to two years after treatment, with no clear signs of cancer development. The researchers emphasized that these findings are preliminary but highlight the potential of vaccines for preventing one of the most dangerous types of cancer, although further studies are needed to confirm its long-term efficacy and safety.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)